Research Progress of Inorganic Nanomaterials in the Treatment of Periodontitis
International Journal of Frontiers in Medicine · 2026 · 8 (1)
DOI: 10.25236/ijfm.2026.080108 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Frontiers in Medicine, 2026.
Abstract (Originalsprache)
Periodontitis is a chronic inflammatory disease characterized by the progressive destruction of periodontal tissues. Conventional oral pharmacotherapy has limitations, including gastrointestinal adverse reactions, allergic responses, low local drug concentration in periodontal pockets, and the risk of inducing drug-resistant bacteria. In recent years, nanomaterials have provided novel strategies for periodontitis treatment owing to their unique physicochemical properties and high loading capacity. This review summarizes recent research progress on inorganic nanomaterials for periodontitis treatment. By analyzing the physicochemical properties, mechanisms of action, and in vitro and in vivo performance of various inorganic nanomaterials, this article highlights their substantial potential to enhance therapeutic efficacy and promote bone tissue regeneration. Concurrently, this review identifies current challenges, including concerns regarding biosafety and complex fabrication processes, and discusses future research directions, thereby providing a theoretical foundation and novel insights for precision periodontitis therapy.
Zitieren
APA
(2026). Research Progress of Inorganic Nanomaterials in the Treatment of Periodontitis. International Journal of Frontiers in Medicine, 8(1). https://doi.org/10.25236/ijfm.2026.080108
Vancouver
Research Progress of Inorganic Nanomaterials in the Treatment of Periodontitis. International Journal of Frontiers in Medicine. 2026;8(1). doi:10.25236/ijfm.2026.080108
BibTeX
@article{euvimed2026,
title = {Research Progress of Inorganic Nanomaterials in the Treatment of Periodontitis},
journal = {International Journal of Frontiers in Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.25236/ijfm.2026.080108}
}
EUVIMED